ClinicalTrials.gg
RecruitingNCT06041945SAVEUpdated Oct 30, 2026

Artificial Intelligence to Implement Cost-saving Strategies for Colonoscopy Screening Based on in Vivo Prediction of Polyp Histology

An interventional study of Standard, high-definition colonoscopy with the use of CADe assistance and Standard, high-definition colonoscopy with the use of CADe/CADx assistance, no leave-in-situ in Colonic Neoplasms, sponsored by Istituto Clinico Humanitas. Recruiting at 2 sites in Italy. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Istituto Clinico Humanitas · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,800
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 135 studies in Colonic Neoplasms with a site in Italy — 41 open to participants now, 56 under way, 8 of them phase 3. Colonic Neoplasms · Italy.

Planned enrollment
6th of 87
1,800 · median 222
Started
2023
with 12 others
No phase
29 of 135
8 open now
Primary completion
2027-09
later than 33 of 55 live
Registered
100th of 135
by date
Lead sponsor
4 of 135
Istituto Clinico Humanitas

Among the 135 studies in Colonic Neoplasms with a site in Italy, this one is the 6th largest by planned enrollment of the 87 interventional ones that give a count, is one of 13 that started in 2023, is one of 29 with no phase, reaches primary completion later than 33 of the 55 other live ones, and was the 100th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

41 of the 135 studies in Colonic Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 40 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 135 studies in Colonic Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

This three parallel-arms, randomized, multicenter trial is aimed at investigating the value of AI-assisted optical biopsy for differentiating between neoplastic and non-neoplastic polyps which will lead to the implementation of cost-saving strategies in screening programs. A cost-effectiveness analyses with the use of modern trial emulation analyses of large observational and clinical trial datasets and real-cost data will be conducted. To improve personalized treatment with a novel colonoscopy CADx risk-prediction tool, the investigators will even develop a novel deep learning algorithm for the optical biopsy of the alternative pathway of colorectal cancer carcinogenesis, namely the serrated pathway and develop cost-effectiveness models of AI-assisted optical biopsy in colorectal cancer screening that provides reliable information to identify cancer risk regardless of physicians' skill.

03

Conditions studied

  • Colonic Neoplasms

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All >40 years-old patients undergoing colonoscopy for selected indications

Exclusion criteria

Exclusion Criteria:

  • patients with personal history of CRC, or IBD
  • patients affected with Lynch syndrome or Familiar Adenomatous Polyposis.
  • patients with inadequate bowel preparation (defined as Boston Bowel Preparation Scale \<2 in any colonic segment).
  • patients with previous colonic resection.
  • patients on antithrombotic therapy, precluding polyp resection.
  • patients who were not able or refused to give informed written consent.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,800 participants (estimated)

Study arms

  • Active comparator
    Standard Arm CADe

    Standard, high-definition colonoscopy with the use of CADe assistance (GI-GENIUS, Medtronic; CAD-EYE, Fujifilm; WISE VISION ,NEC). All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.

    Device: Standard, high-definition colonoscopy with the use of CADe assistance

  • Active comparator
    Standard Arm CADe/CADx

    Standard, high-definition colonoscopy with the use of CADe/CADx assistance (GI-GENIUS, Medtronic; CAD-EYE, Fujifilm; WISE VISION ,NEC). All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.

    Device: Standard, high-definition colonoscopy with the use of CADe/CADx assistance, no leave-in-situ

  • Experimental
    Leave-In-Situ Arm

    Standard, high-definition colonoscopy with the use of CADe/CADx assistance (GI-GENIUS, Medtronic; CAD-EYE, Fujifilm; WISE VISION, NEC). Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.

    Device: Standard, high-definition colonoscopy with the use of CADe/CADx assistance, leave-in-situ

Interventions

  • DeviceStandard, high-definition colonoscopy with the use of CADe assistance

    All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.

  • DeviceStandard, high-definition colonoscopy with the use of CADe/CADx assistance, no leave-in-situ

    All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.

  • DeviceStandard, high-definition colonoscopy with the use of CADe/CADx assistance, leave-in-situ

    Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.

06

What researchers measure

Primary outcomes

  1. Non-inferiority in Adenoma Detection Rate

    Non-inferiority in the Adenoma Detection Rate, defined as the proportion of participants with at least one adenoma (per-patient analysis) in the three arms, when adopting a cost-saving leave-in-situ strategy for non-neoplastic rectosigmoid diminutive polyps.

    Time frame: 4 years

Secondary outcomes

  1. Negative Predictive Value for colorectal neoplasia

    Negative Predictive Value for colorectal neoplasia when adopting a leave-in-situ strategy for rectosigmoid diminutive polyps based on the use of Artificial Intelligence.

    Time frame: 4 years

  2. Concordance between post-polypectomy surveillance and when adopting a leave-in-situ strategy

    Concordance between post-polypectomy surveillance based on strategies based on optical diagnosis with Artificial Intelligence and those based on histology, and when adopting a leave-in-situ strategy for colorectal diminutive polyps based on the use of Artificial Intelligence

    Time frame: 4 years

  3. Change in the cost of polypectomy and histology in screening programs

    Change in the cost of polypectomy and histology in screening programs, when implementing strategies based on Artificial Intelligence-based optical biopsy, without changes in benefit related with detection of colorectal neoplasia

    Time frame: 4 years

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Sep 2027, 47 months after the start.

Of 382 non-industry interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 55. This study's planned 47 months is above that.

Counting every sponsor, half of 404 studies reached it within 30 months; a quarter within 16 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2023
First posted
Sep 18, 2023
StartActual
Sep 21, 2023
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms and verification date
1 update, last Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Minor edits only
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06041945
Responsible party
Sponsor
First posted
Sep 18, 2023
Start date
Sep 21, 2023
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Cesare Hassan
Contact
cesare.hassan@hunimed.eu
02-82247385

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion